{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T06:10:27Z","timestamp":1783923027784,"version":"3.55.0"},"reference-count":101,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    Immune checkpoint inhibitors (ICIs) have revolutionized the oncological landscape by disrupting inhibitory pathways, notably programmed cell death protein-1\/programmed death-ligand 1 (PD-1\/PD-L1) and cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) pathways, thereby reinvigorating host antitumor immunity. Although these agents have emerged as frontline standard therapies for malignancies, their clinical utility remains limited. Interpatient therapeutic variability is inextricably linked to the composition and functional capacity of the gut microbiome. The underlying mechanisms appear to involve a complex dialogue between the microbiota and host immune system, where microbial metabolites serve as critical mediators in remodeling the tumor microenvironment. Despite these insights, progression in the field remains constrained due to heterogeneity in study cohorts and sample-processing methodologies, hindering the establishment of reproducible individualized predictive models and clinical intervention strategies. Consequently, there is an urgent need to systematically delineate the microbiome\u2013metabolite\u2013immune axis to optimize the balance between ICI efficacy and systemic toxicity. By synthesizing the latest evidence, this review aimed to highlight the pivotal roles of specific taxa, including\n                    <jats:italic>Bacteroides<\/jats:italic>\n                    ,\n                    <jats:italic>Bifidobacterium<\/jats:italic>\n                    , and\n                    <jats:italic>Akkermansia muciniphila<\/jats:italic>\n                    , in ICI efficacy. These microbes and their metabolic byproducts potentiate therapeutic responses by enhancing dendritic cell cross-presentation and promoting CD\n                    <jats:sup>8+<\/jats:sup>\n                    T-cell infiltration, often via activation of the cyclic GMP-AMP synthase-stimulator of interferon genes or nucleotide-binding oligomerization domain-containing protein 2 signaling pathways. Furthermore, these microbial components demonstrate the ability to protect the heart and colon against inflammation and barrier disruption, thereby mitigating immune-related adverse events. Although the feasibility and safety of interventions such as fecal microbiota transplantation and supplementation with next-generation encapsulated probiotics, postbiotics, or dietary fiber have been demonstrated in preclinical and Phase I trials, substantial hurdles remain. Future progress requires large-scale, multicenter, standardized, longitudinal studies integrating metagenomics and metabolomics to construct robust cross-cancer and cross-population predictive models. Such rigorous validation would enable the development of precise microbial interventions that maximize therapeutic gains while minimizing the incidence of adverse reactions.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2026.1803970","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T05:34:04Z","timestamp":1783920844000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Navigating the gut\u2013metabolite\u2013immune axis: enhancing efficacy and mitigating toxicity of immune checkpoint inhibitors"],"prefix":"10.3389","volume":"17","author":[{"given":"Yu","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Geriatrics, The First Hospital of Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengnan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Geriatrics, The First Hospital of Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Geriatrics, The First Hospital of Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Geriatrics, The First Hospital of Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yexing","family":"Dang","sequence":"additional","affiliation":[{"name":"Department of Geriatrics, The First Hospital of Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihao","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Geriatrics, The First Hospital of Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.pharmthera.2018.09.008","article-title":"Targeting programmed cell death -1 (PD-1) and ligand (PD-L1): A new era in cancer active immunotherapy","volume":"194","author":"Constantinidou","year":"2019","journal-title":"Pharmacol Ther"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-021-00345-8","article-title":"The foundations of immune checkpoint blockade and the ipilimumab approval decennial","volume":"21","author":"Korman","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.cir-17-0057","article-title":"Masterful antibodies: Checkpoint blockade","volume":"5","author":"Lonberg","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.08.038","article-title":"Releasing the brakes on cancer immunotherapy","volume":"162","author":"Littman","year":"2015","journal-title":"Cell"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102350","article-title":"Role and impact of immune checkpoint inhibitors in neoadjuvant treatment for NSCLC","volume":"104","author":"Friedlaender","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(21)01206-x","article-title":"Immune checkpoint inhibitors in melanoma","volume":"398","author":"Carlino","year":"2021","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2023.05.011","article-title":"Checkpoint inhibitors in urothelial carcinoma-future directions and biomarker selection","volume":"84","author":"Meeks","year":"2023","journal-title":"Eur Urol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1038\/s41419-018-1099-3","article-title":"Diosgenin promotes antitumor immunity and PD-1 antibody efficacy against melanoma by regulating intestinal microbiota","volume":"9","author":"Dong","year":"2018","journal-title":"Cell Death Dis"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2018.78.2276","article-title":"T-cell-inflamed gene-expression profile, programmed death ligand 1 expression, and tumor mutational burden predict efficacy in patients treated with pembrolizumab across 20 cancers: KEYNOTE-028","volume":"37","author":"Ott","year":"2019","journal-title":"J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"eaar3593","DOI":"10.1126\/science.aar3593","article-title":"Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy","volume":"362","author":"Cristescu","year":"2018","journal-title":"Science"},{"key":"B11","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1016\/j.cmet.2021.03.002","article-title":"Gut microbial metabolites facilitate anticancer therapy efficacy by modulating cytotoxic CD8(+) T cell immunity","volume":"33","author":"He","year":"2021","journal-title":"Cell Metab"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1126\/science.aad1329","article-title":"Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota","volume":"350","author":"V\u00e9tizou","year":"2015","journal-title":"Science"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1126\/science.aao3290","article-title":"The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients","volume":"359","author":"Matson","year":"2018","journal-title":"Science"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan3706","article-title":"Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors","volume":"359","author":"Routy","year":"2018","journal-title":"Science"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e009722","DOI":"10.1136\/jitc-2024-009722","article-title":"Immune checkpoint blockade: Timing is everything","volume":"12","author":"Sinicrope","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B16","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12964-022-00854-y","article-title":"Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons","volume":"20","author":"Naimi","year":"2022","journal-title":"Cell Commun Signal"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.70274","article-title":"Improvement of the anticancer efficacy of PD-1\/PD-L1 blockade: Advances in molecular mechanisms and therapeutic strategies","volume":"6","author":"Gao","year":"2025","journal-title":"MedComm (2020)"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-023-01569-z","article-title":"LAG-3 as the third checkpoint inhibitor","volume":"24","author":"Aggarwal","year":"2023","journal-title":"Nat Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1501613","article-title":"Lymphocyte-activation gene 3 in cancer immunotherapy: Function, prognostic biomarker and therapeutic potentials","volume":"15","author":"Ren","year":"2024","journal-title":"Front Immunol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/s41392-024-02000-1","article-title":"PD-1 and LAG-3: Synergistic fostering of T cell exhaustion","volume":"9","author":"Hofmann","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1200\/jco.24.01125","article-title":"First-line nivolumab plus relatlimab versus nivolumab plus ipilimumab in advanced melanoma: An indirect treatment comparison using RELATIVITY-047 and CheckMate 067 trial data","volume":"42","author":"Long","year":"2024","journal-title":"J Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1007\/s00262-025-04128-7","article-title":"Anti-TIGIT therapies: A review of preclinical and clinical efficacy and mechanisms","volume":"74","author":"Sundstrom","year":"2025","journal-title":"Cancer Immunol Immunother"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-018-0132-0","article-title":"Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity","volume":"19","author":"Zhang","year":"2018","journal-title":"Nat Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2014.10.018","article-title":"The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function","volume":"26","author":"Johnston","year":"2014","journal-title":"Cancer Cell"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(22)00226-1","article-title":"Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): Primary and follow-up analyses of a randomised, double-blind, phase 2 study","volume":"23","author":"Cho","year":"2022","journal-title":"Lancet Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2024.01.010","article-title":"LAG-3, TIM-3, and TIGIT: Distinct functions in immune regulation","volume":"57","author":"Joller","year":"2024","journal-title":"Immunity"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/ni987","article-title":"Tim-3 inhibits T helper type 1-mediated auto- and alloimmune responses and promotes immunological tolerance","volume":"4","author":"S\u00e1nchez-Fueyo","year":"2003","journal-title":"Nat Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-18-1038","article-title":"Resistance to radiotherapy and PD-L1 blockade is mediated by TIM-3 upregulation and regulatory T-cell infiltration","volume":"24","author":"Oweida","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2024.09.026","article-title":"PD-L1: From cancer immunotherapy to therapeutic implications in multiple disorders","volume":"32","author":"Lee","year":"2024","journal-title":"Mol Ther"},{"key":"B30","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s13046-021-01987-7","article-title":"Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer","volume":"40","author":"Zhang","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1126\/science.1203486","article-title":"Cancer immunoediting: Integrating immunity's roles in cancer suppression and promotion","volume":"331","author":"Schreiber","year":"2011","journal-title":"Science"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"B33","first-page":"11","article-title":"Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma","volume":"10","author":"Berman","year":"2010","journal-title":"Cancer Immun"},{"key":"B34","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1126\/science.aan4236","article-title":"Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients","volume":"359","author":"Gopalakrishnan","year":"2018","journal-title":"Science"},{"key":"B35","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13073-022-01037-7","article-title":"Interaction of bacterial genera associated with therapeutic response to immune checkpoint PD-1 blockade in a United States cohort","volume":"14","author":"Newsome","year":"2022","journal-title":"Genome Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01655-5","article-title":"Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer","volume":"28","author":"Derosa","year":"2022","journal-title":"Nat Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/s41564-020-00831-6","article-title":"Bifidobacterium bifidum strains synergize with immune checkpoint inhibitors to reduce tumour burden in mice","volume":"6","author":"Lee","year":"2021","journal-title":"Nat Microbiol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1126\/science.aac4255","article-title":"Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy","volume":"350","author":"Sivan","year":"2015","journal-title":"Science"},{"key":"B39","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.chom.2024.03.002","article-title":"A specific enterotype derived from gut microbiome of older individuals enables favorable responses to immune checkpoint blockade therapy","volume":"32","author":"Zhu","year":"2024","journal-title":"Cell Host Microbe"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/nature09944","article-title":"Enterotypes of the human gut microbiome","volume":"473","author":"Arumugam","year":"2011","journal-title":"Nature"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2017.08.004","article-title":"Metagenomic shotgun sequencing and unbiased metabolomic profiling identify specific human gut microbiota and metabolites associated with immune checkpoint therapy efficacy in melanoma patients","volume":"19","author":"Frankel","year":"2017","journal-title":"Neoplasia"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01695-5","article-title":"Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma","volume":"28","author":"Lee","year":"2022","journal-title":"Nat Med"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.5312","article-title":"Bifidobacterium breve predicts the efficacy of anti-PD-1 immunotherapy combined with chemotherapy in Chinese NSCLC patients","volume":"12","author":"Zhao","year":"2023","journal-title":"Cancer Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-24-0066","article-title":"Randomized placebo-controlled, biomarker-stratified phase Ib microbiome modulation in melanoma: Impact of antibiotic preconditioning on microbiome and immunity","volume":"14","author":"Glitza","year":"2024","journal-title":"Cancer Discov"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2020-323071","article-title":"Gut microbiota-derived metabolites as central regulators in metabolic disorders","volume":"70","author":"Agus","year":"2021","journal-title":"Gut"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1007\/s13238-018-0549-0","article-title":"Gut microbiota derived metabolites in cardiovascular health and disease","volume":"9","author":"Wang","year":"2018","journal-title":"Protein Cell"},{"key":"B47","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41467-017-02490-4","article-title":"Short-chain fatty acids regulate systemic bone mass and protect from pathological bone loss","volume":"9","author":"Lucas","year":"2018","journal-title":"Nat Commun"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.109314","article-title":"Indole-3-aldehyde alleviates chondrocytes inflammation through the AhR-NF-\u03baB signalling pathway","volume":"113","author":"Zhuang","year":"2022","journal-title":"Int Immunopharmacol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"e003725","DOI":"10.1136\/jitc-2021-003725","article-title":"Optimizing therapeutic outcomes of immune checkpoint blockade by a microbial tryptophan metabolite","volume":"10","author":"Renga","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1016\/j.cell.2023.03.011","article-title":"Dietary tryptophan metabolite released by intratumoral Lactobacillus reuteri facilitates immune checkpoint inhibitor treatment","volume":"186","author":"Bender","year":"2023","journal-title":"Cell"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.2147\/jir.s466777","article-title":"Pretreatment with indole-3-propionic acid attenuates lipopolysaccharide-induced cardiac dysfunction and inflammation through the AhR\/NF-\u03baB\/NLRP3 pathway","volume":"17","author":"Zhang","year":"2024","journal-title":"J Inflammation Res"},{"key":"B52","doi-asserted-by":"publisher","first-page":"2651","DOI":"10.1038\/s41467-025-58107-8","article-title":"Microbiota-indole-3-propionic acid-heart axis mediates the protection of leflunomide against \u03b1PD1-induced cardiotoxicity in mice","volume":"16","author":"Huang","year":"2025","journal-title":"Nat Commun"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2309032120","article-title":"Bacterial indole-3-lactic acid affects epithelium-macrophage crosstalk to regulate intestinal homeostasis","volume":"120","author":"Yu","year":"2023","journal-title":"Proc Natl Acad Sci USA"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jafc.2c06894","article-title":"Bifidobacterium bifidum ameliorates DSS-induced colitis in mice by regulating AHR\/NRF2\/NLRP3 inflammasome pathways through indole-3-lactic acid production","volume":"71","author":"Cui","year":"2023","journal-title":"J Agric Food Chem"},{"key":"B55","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1186\/s12866-020-02023-y","article-title":"Indole-3-lactic acid associated with Bifidobacterium-dominated microbiota significantly decreases inflammation in intestinal epithelial cells","volume":"20","author":"Ehrlich","year":"2020","journal-title":"BMC Microbiol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-021-02201-4","article-title":"Prevotellaceae produces butyrate to alleviate PD-1\/PD-L1 inhibitor-related cardiotoxicity via PPAR\u03b1-CYP4X1 axis in colonic macrophages","volume":"41","author":"Chen","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1096\/fj.201802681rr","article-title":"The PPAR-microbiota-metabolic organ trilogy to fine-tune physiology","volume":"33","author":"Oh","year":"2019","journal-title":"FASEB J"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01036","article-title":"The microbial metabolite butyrate induces expression of Th1-associated factors in CD4(+) T cells","volume":"8","author":"Kespohl","year":"2017","journal-title":"Front Immunol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.immuni.2019.06.002","article-title":"Microbiota-derived short-chain fatty acids promote the memory potential of antigen-activated CD8(+) T cells","volume":"51","author":"Bachem","year":"2019","journal-title":"Immunity"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1126\/science.1241165","article-title":"The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis","volume":"341","author":"Smith","year":"2013","journal-title":"Science"},{"key":"B61","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.cmet.2022.02.010","article-title":"The microbial metabolite trimethylamine N-oxide promotes antitumor immunity in triple-negative breast cancer","volume":"34","author":"Wang","year":"2022","journal-title":"Cell Metab"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2023.154775","article-title":"Zuogui-Jiangtang-Yishen decoction prevents diabetic kidney disease: Intervene pyroptosis induced by trimethylamine n-oxide through the mROS-NLRP3 axis","volume":"114","author":"Yi","year":"2023","journal-title":"Phytomedicine"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.104087","article-title":"Akkermansia muciniphila prevents cold-related atrial fibrillation in rats by modulation of TMAO induced cardiac pyroptosis","volume":"82","author":"Luo","year":"2022","journal-title":"EBioMedicine"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc3421","article-title":"Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy","volume":"369","author":"Mager","year":"2020","journal-title":"Science"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2016.4","article-title":"Purinergic regulation of the immune system","volume":"16","author":"Cekic","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1038\/s41522-023-00374-8","article-title":"Gut microbiota-mediated secondary bile acid alleviates Staphylococcus aureus-induced mastitis through the TGR5-cAMP-PKA-NF-\u03baB\/NLRP3 pathways in mice","volume":"9","author":"Zhao","year":"2023","journal-title":"NPJ Biofilms Microbiomes"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2193-0","article-title":"Bacterial metabolism of bile acids promotes generation of peripheral regulatory T cells","volume":"581","author":"Campbell","year":"2020","journal-title":"Nature"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.10.009","article-title":"Bile acids control inflammation and metabolic disorder through inhibition of NLRP3 inflammasome","volume":"45","author":"Guo","year":"2016","journal-title":"Immunity"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10391","article-title":"Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis","volume":"7","author":"Dubin","year":"2016","journal-title":"Nat Commun"},{"key":"B70","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/nejmoa2407417","article-title":"Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma","volume":"392","author":"Wolchok","year":"2025","journal-title":"N Engl J Med"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N Engl J Med"},{"key":"B72","doi-asserted-by":"publisher","first-page":"e003334","DOI":"10.1136\/jitc-2021-003334","article-title":"Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in hepatobiliary cancers","volume":"9","author":"Mao","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/j.tifs.2021.11.034","article-title":"Optimizing oral delivery of next generation probiotics","volume":"119","author":"Torp","year":"2022","journal-title":"Trends Food Sci Technol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2014.66","article-title":"Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic","volume":"11","author":"Hill","year":"2014","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.7045","article-title":"The effect of perioperative probiotics treatment for colorectal cancer: short-term outcomes of a randomized controlled trial","volume":"7","author":"Yang","year":"2016","journal-title":"Oncotarget"},{"key":"B76","doi-asserted-by":"publisher","first-page":"356","DOI":"10.3390\/nu15020356","article-title":"Postoperative probiotics administration attenuates gastrointestinal complications and gut microbiota dysbiosis caused by chemotherapy in colorectal cancer patients","volume":"15","author":"Huang","year":"2023","journal-title":"Nutrients"},{"key":"B77","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1038\/s41467-022-29672-z","article-title":"A single-cell nanocoating of probiotics for enhanced amelioration of antibiotic-associated diarrhea","volume":"13","author":"Pan","year":"2022","journal-title":"Nat Commun"},{"key":"B78","doi-asserted-by":"publisher","first-page":"923","DOI":"10.3390\/nu17050923","article-title":"Milk exosome-based delivery system for probiotic encapsulation that enhances the gastrointestinal resistance and adhesion of probiotics","volume":"17","author":"Hao","year":"2025","journal-title":"Nutrients"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2023.124784","article-title":"Polysaccharides, proteins, and their complex as microencapsulation carriers for delivery of probiotics: A review on carrier types and encapsulation techniques","volume":"242","author":"Xie","year":"2023","journal-title":"Int J Biol Macromol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2020-323426","article-title":"Lactobacillus rhamnosus GG induces cGAS\/STING- dependent type I interferon and improves response to immune checkpoint blockade","volume":"71","author":"Si","year":"2022","journal-title":"Gut"},{"key":"B81","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s13045-020-00916-z","article-title":"cGAS-STING, an important pathway in cancer immunotherapy","volume":"13","author":"Jiang","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2025.1523754","article-title":"The therapeutic promise of probiotic Bacteroides fragilis (BF839) in cancer immunotherapy","volume":"16","author":"Peng","year":"2025","journal-title":"Front Microbiol"},{"key":"B83","doi-asserted-by":"publisher","first-page":"e010511","DOI":"10.1136\/jitc-2024-010511","article-title":"Phase I dose-escalation and pharmacodynamic study of STING agonist E7766 in advanced solid tumors","volume":"13","author":"Luke","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B84","doi-asserted-by":"publisher","first-page":"5338","DOI":"10.1016\/j.cell.2021.09.019","article-title":"Microbiota triggers STING-type I IFN-dependent monocyte reprogramming of the tumor microenvironment","volume":"184","author":"Lam","year":"2021","journal-title":"Cell"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc9113","article-title":"Enterococcus peptidoglycan remodeling promotes checkpoint inhibitor cancer immunotherapy","volume":"373","author":"Griffin","year":"2021","journal-title":"Science"},{"key":"B86","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1016\/j.ccell.2025.07.002","article-title":"Alistipes finegoldii augments the efficacy of immunotherapy against solid tumors","volume":"43","author":"Wu","year":"2025","journal-title":"Cancer Cell"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-0929","article-title":"Dietary Lactobacillus-derived exopolysaccharide enhances immune-checkpoint blockade therapy","volume":"12","author":"Kawanabe-Matsuda","year":"2022","journal-title":"Cancer Discov"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03086-4","article-title":"Cabozantinib and nivolumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial","volume":"30","author":"Ebrahimi","year":"2024","journal-title":"Nat Med"},{"key":"B89","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ebiom.2016.09.029","article-title":"Fecal microbiota-based therapeutics for recurrent Clostridium difficile infection, ulcerative colitis and obesity","volume":"13","author":"Carlucci","year":"2016","journal-title":"EBioMedicine"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1126\/science.abb5920","article-title":"Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients","volume":"371","author":"Baruch","year":"2021","journal-title":"Science"},{"key":"B91","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1126\/science.abf3363","article-title":"Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients","volume":"371","author":"Davar","year":"2021","journal-title":"Science"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-04186-5","article-title":"Fecal microbiota transplantation plus immunotherapy in non-small cell lung cancer and melanoma: the phase 2 FMT-LUMINate trial","volume":"32","author":"Duttagupta","year":"2026","journal-title":"Nat Med"},{"key":"B93","doi-asserted-by":"publisher","first-page":"e013823","DOI":"10.1136\/jitc-2025-013823","article-title":"Fecal microbiota transplantation combined with anti-PD-1 therapy in refractory microsatellite-stable gastric cancer: a phase I feasibility and safety study","volume":"14","author":"Zhang","year":"2026","journal-title":"J Immunother Cancer"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-021-00440-6","article-title":"The International Scientific Association of Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of postbiotics","volume":"18","author":"Salminen","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B95","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.trecan.2023.12.001","article-title":"Beyond probiotics: postbiotics sensitize cancer cells to immune checkpoint inhibitors","volume":"10","author":"Liu","year":"2024","journal-title":"Trends Cancer"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2024.2380061","article-title":"MS-20 enhances the gut microbiota-associated antitumor effects of anti-PD1 antibody","volume":"16","author":"Lee","year":"2024","journal-title":"Gut Microbes"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1080\/10408398.2023.2293254","article-title":"Advances in dietary polysaccharides as hypoglycemic agents: mechanisms, structural characteristics, and innovative applications","volume":"65","author":"Zhang","year":"2025","journal-title":"Crit Rev Food Sci Nutr"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaz7015","article-title":"Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response","volume":"374","author":"Spencer","year":"2021","journal-title":"Science"},{"key":"B99","doi-asserted-by":"publisher","first-page":"3373","DOI":"10.1016\/j.cell.2024.05.029","article-title":"Custom scoring based on ecological topology of gut microbiota associated with cancer immunotherapy outcome","volume":"187","author":"Derosa","year":"2024","journal-title":"Cell"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiz151","article-title":"From the pipeline to the bedside: advances and challenges in clinical metagenomics","volume":"221","author":"Dulanto Chiang","year":"2020","journal-title":"J Infect Dis"},{"key":"B101","doi-asserted-by":"publisher","first-page":"6534","DOI":"10.1038\/s41598-024-55635-z","article-title":"Short turnaround time of seven to nine hours from sample collection until informed decision for sepsis treatment using nanopore sequencing","volume":"14","author":"Ali","year":"2024","journal-title":"Sci Rep"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1803970\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T05:34:05Z","timestamp":1783920845000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1803970\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,13]]},"references-count":101,"alternative-id":["10.3389\/fimmu.2026.1803970"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1803970","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,13]]},"article-number":"1803970"}}